Lilly Asia Ventures

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.

Developer of RNA therapeutics platform designed for RNA medicine discovery. The company aims to establish innovative and disruptive RNA medicines with proprietary platform to enable therapeutics with more specific, stable and prolonged effects. The company is building state-of-the-art facilities to expand nucleic acid synthesis, delivery platform, oligonucleotide chemical modification, RNA biology and manufacturing capability to realize the potential of powerful RNA therapeutics.

IMPACT Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other serious diseases. Founded in 2009 and headquartered in Shanghai, China, the company is engaged in several research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, novel DNA damage response agents, and Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights, emphasizing the discovery of targeted anti-cancer therapies based on the principle of synthetic lethality. The company’s management team possesses extensive experience in drug development and management, with a strong background in pharmacology and biology, which supports its mission to provide innovative treatments for patients with life-threatening conditions.

ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in utilizing a proprietary platform that leverages endogenous enzymes, specifically adenosine deaminase acting on RNA (ADAR), to precisely target and correct single point mutations in mRNA transcripts. This innovative approach aims to restore the production of functional proteins, addressing various genetic mutations that contribute to diseases. ADARx is developing a pipeline of therapeutics designed to treat a range of conditions, including genetic, cardiometabolic, complement-mediated, and central nervous system diseases, offering potential solutions for previously incurable ailments.

Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Zentera Therapeutics is a biopharmaceutical company.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.

ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, with a focus on developing innovative antibody-drug conjugate therapies for late-stage multiple myeloma and prostate cancer. The company was established based on technology exclusively licensed from the University of California, San Francisco, and developed in the laboratory of Dr. Bin Liu. Fortis Therapeutics aims to enhance treatment options for patients suffering from advanced adenocarcinoma and neuroendocrine cancer, leveraging its proprietary platform to create targeted therapies that improve clinical outcomes in late-stage cancer treatment.

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China and internationally. It offers infusion and non-infusion products, and new injection package. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.

Developer of biological R&D platform intended to discover antibody new drugs. The company develops antibody drugs to better treat cancer and tumor diseases, enabling patients to get better treatments.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting oncology, metabolic diseases, and autoimmune diseases. Utilizing its proprietary CARD (Computer Accelerated Rational Discovery) platform, Regor integrates various scientific disciplines, including structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. This approach allows the company to efficiently produce both best-in-class and first-in-class therapeutic molecules. With a strong emphasis on scientific expertise, Regor Therapeutics aims to deliver clinically differentiated treatments that address unmet medical needs.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small-molecule drugs for the treatment of cancer and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company leverages its expertise in disease biology and medicinal chemistry to advance a pipeline of innovative therapeutic candidates. Key products include TERN-101, a non-bile acid farnesoid X receptor agonist, and TERN-201, an inhibitor of semicarbazide-sensitive amine oxidase. Terns Pharmaceuticals aims to address significant unmet medical needs both in China and globally through its efficient drug discovery model and extensive clinical development capabilities.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.

IMPACT Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other serious diseases. Founded in 2009 and headquartered in Shanghai, China, the company is engaged in several research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, novel DNA damage response agents, and Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights, emphasizing the discovery of targeted anti-cancer therapies based on the principle of synthetic lethality. The company’s management team possesses extensive experience in drug development and management, with a strong background in pharmacology and biology, which supports its mission to provide innovative treatments for patients with life-threatening conditions.

CARsgen Therapeutics, Ltd., a clinical-stage immunotherapy company, develops and commercializes chimeric antigen receptor T-cell (CAR-T) therapeutics for treating cancers. It offers CAR-T Technology that directs T cells to recognize cancer cells based on expression of specific cell surface proteins to treat solid and hematologic tumors. The company’s CAR-T cells target the GPC3 receptor for the treatment of late-stage hepatocellular carcinoma (HCC, or liver cancer) and lung squamous cell carcinoma (a common type of lung cancer). CARsgen Therapeutics, Ltd. is based in Shanghai, China.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative cell therapies for cancer treatment. The company's lead product candidates include GC012F, a dual-targeted CAR-T therapy for multiple myeloma currently in Phase I trials; GC019F, which targets adult B cell acute lymphoblastic leukemia and is also in Phase I trials; and GC007F, aimed at B cell non-Hodgkin’s lymphoma, also in Phase I. Additionally, Gracell is developing GC027, a CAR-T candidate targeting adult T cell acute lymphoblastic leukemia, and GC007g, an allogeneic CAR-T therapy for relapsed or refractory B-ALL, both in Phase I trials. Beyond these, Gracell has a pipeline of earlier-stage product candidates targeting various cancers, including ovarian and breast cancer. Founded in 2017, Gracell Biotechnologies is committed to advancing cellular therapeutics to improve patient outcomes in hematological malignancies and solid tumors.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd. develops and commercializes novel cancer immunotherapy products. The company designs platforms to reverse cancer cell-induced immune inhibition and to eradicate cancer cells. It offers platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells to fulfill the cancer-killing task. The company’s platforms include Target-Activated NK (TANK™) Cell Therapy, PD-1/PD-L1 antibody blockade assay platform, and Activating Macrophages. The company was founded in 2015 and is headquartered in Shanghai, China.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets stabilized hypochlorous acid (HOCl) products for a range of healthcare applications, including wound care, dermatology, animal health, and eye care. The company offers a diverse portfolio of products designed to address various medical needs, such as Epicyn, an antimicrobial facial cleanser; Levicyn, for managing dermatoses; and Celacyn, which promotes healing of surgical scars and trauma wounds. Other notable products include SebuDerm for seborrheic dermatitis, Ceramax for dry skin, and Acuicyn for eye irritation. Sonoma also provides solutions for animal health, like MicrocynAH and MicrocynVS, targeting skin conditions in pets. With over 100 products commercialized globally across 33 countries, the company aims to enhance patient care while addressing unmet medical needs and reducing healthcare costs. Founded in 1999 and based in Woodstock, Georgia, Sonoma Pharmaceuticals was previously known as Oculus Innovative Sciences, Inc. before rebranding in 2016.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

Dizal Pharmaceutical is a research-focused biotechnology company involved in the discovery, development, and commercialization of innovative medicines. The company specializes in creating first-in-class and best-in-class therapeutic solutions, emphasizing cutting-edge research and development. In addition to its drug development efforts, Dizal is also engaged in the production and sales of these innovative treatments, aiming to improve patient outcomes through advanced pharmaceutical solutions.

Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for oncology and other medical conditions. Its primary product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy aimed at treating multiple myeloma by targeting the B-cell maturation antigen. The company is actively conducting clinical trials to assess this therapy as an earlier treatment option and to compare its effectiveness against standard triplet therapy in patients resistant to Revlimid. Additionally, Legend Biotech has a diverse portfolio of earlier-stage autologous product candidates that address various cancers, including non-Hodgkin lymphoma, acute myeloid leukemia, and T cell lymphoma. The company is also developing an allogeneic CAR-T product candidate targeting CD20, currently in a Phase 1 clinical trial in China. Besides its focus on blood cancers, Legend Biotech is exploring therapies for solid tumors and infectious diseases. Founded in 2014 and based in Somerset, New Jersey, Legend Biotech operates as a subsidiary of Genscript Biotech Corporation.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China, that focuses on the discovery, development, and commercialization of biologics aimed at addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases. Established in 2008, RemeGen specializes in innovative biologics, including monoclonal antibodies and antibody-drug conjugates. Its key products under development include Telitacicept, which targets autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, and Disitamab Vedotin for various cancers. The company is also advancing other candidates like RC28 and RC88 for retinal conditions, alongside several pre-clinical products aimed at treating solid tumors. RemeGen operates primarily in China but also maintains laboratories and offices in Beijing and California, emphasizing its commitment to fulfilling the medical needs of patients with life-threatening conditions.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

Geneseeq Technology Inc., established in 2008 and based in Toronto, Canada, operates a clinical testing and diagnostic center specializing in next-generation sequencing (NGS) technologies. The company focuses on advancing precision medicine in cancer treatment by transforming patients' genomic information into actionable insights for healthcare providers. Geneseeq's laboratories have attained significant certifications, including those from China's National Center of Clinical Laboratories and the College of American Pathologists, ensuring high standards in clinical diagnostics. The company offers a range of personalized medical diagnostics and healthcare management services, including genetic screening and molecular diagnostics, aimed at enhancing the detection and treatment success of cancer.

ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company is focused on addressing complex disease biology through its proprietary protein engineering methods, including a single-domain antibody platform. Its key candidates include INBRX-109, a multivalent agonist targeting death receptor 5 for solid tumors; INBRX-105, an antagonist of PD-L1 and conditional agonist of 4-1BB for PD-L1 expressing tumors; INBRX-101, an Fc-fusion protein aimed at alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting cluster of differentiation 47. Additionally, Inhibrx has preclinical programs such as INBRX-106 and INBRX-111, which focus on oncology and infectious diseases. The company has established collaborations with organizations like Celgene and bluebird bio and has received support from various granting agencies, including the NIH and CARB-X.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing innovative cell therapies for cancer treatment. The company's lead product candidates include GC012F, a dual-targeted CAR-T therapy for multiple myeloma currently in Phase I trials; GC019F, which targets adult B cell acute lymphoblastic leukemia and is also in Phase I trials; and GC007F, aimed at B cell non-Hodgkin’s lymphoma, also in Phase I. Additionally, Gracell is developing GC027, a CAR-T candidate targeting adult T cell acute lymphoblastic leukemia, and GC007g, an allogeneic CAR-T therapy for relapsed or refractory B-ALL, both in Phase I trials. Beyond these, Gracell has a pipeline of earlier-stage product candidates targeting various cancers, including ovarian and breast cancer. Founded in 2017, Gracell Biotechnologies is committed to advancing cellular therapeutics to improve patient outcomes in hematological malignancies and solid tumors.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Burning Rock Biotech Limited is a cancer diagnostics company based in China that specializes in developing and providing next-generation sequencing (NGS) based cancer therapy selection tests. Founded in 2014 and headquartered in Guangzhou, the company offers a portfolio of 13 tests applicable to various cancer types, including lung, gastrointestinal, and breast cancers, utilizing both tissue and liquid biopsy samples. Notable products include OncoScreen Plus, which targets therapy and immunotherapy biomarkers, and LungPlasma, a liquid biopsy test for non-small cell lung cancer. Additionally, Burning Rock provides services for gastrointestinal cancer testing and assessments of genes related to homologous recombination deficiency. The company collaborates with major pharmaceutical firms such as AstraZeneca and Bayer on clinical trials and research studies, focusing on companion diagnostics and laboratory services. With a commitment to personalized cancer treatment, Burning Rock aims to deliver comprehensive solutions that integrate genetic testing with clinical and research services.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, dedicated to discovering and developing innovative immunomedicines for cancer and other immune-related diseases. The company’s lead product candidate, NC318, is currently undergoing Phase 2 clinical trials aimed at treating advanced or metastatic solid tumors. Additionally, NextCure is advancing NC410, an immunomedicine designed to counteract immune suppression through targeting an immune modulator known as Leukocyte-Associated Immunoglobulin-like Receptor 1. The company is also engaged in research programs evaluating novel immunomodulatory molecules, including antibodies in preclinical development that target specific immune modulators in inflamed tissues and tumor microenvironments. NextCure has established a license agreement with Yale University and collaborates with Eli Lilly and Company for research and development efforts. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets and develop first-in-class immunotherapy products.

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small-molecule drugs for the treatment of cancer and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company leverages its expertise in disease biology and medicinal chemistry to advance a pipeline of innovative therapeutic candidates. Key products include TERN-101, a non-bile acid farnesoid X receptor agonist, and TERN-201, an inhibitor of semicarbazide-sensitive amine oxidase. Terns Pharmaceuticals aims to address significant unmet medical needs both in China and globally through its efficient drug discovery model and extensive clinical development capabilities.

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

IMPACT Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other serious diseases. Founded in 2009 and headquartered in Shanghai, China, the company is engaged in several research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, novel DNA damage response agents, and Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights, emphasizing the discovery of targeted anti-cancer therapies based on the principle of synthetic lethality. The company’s management team possesses extensive experience in drug development and management, with a strong background in pharmacology and biology, which supports its mission to provide innovative treatments for patients with life-threatening conditions.

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibody drug candidates. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in treating multiple cancers and is featured on the National Reimbursement Drug List. Innovent has developed several other promising candidates, including biosimilars and bispecific antibodies for conditions such as non-Hodgkin’s lymphoma, autoimmune diseases, and advanced solid tumors. The company has established strategic collaborations with major global pharmaceutical firms, enhancing its research and development capabilities. Founded in 2011, Innovent has a strong management team with extensive experience in biologics, and it continues to expand its portfolio of therapeutic options while maintaining a commitment to innovation in the biopharmaceutical industry.

Tmunity Therapeutics, based in Philadelphia and incorporated in 2015, is a bio-therapeutics company focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. The company specializes in engineering T cells, utilizing novel T Cell Receptor (TCR) technologies, regulatory T cells (Treg), and universal engineered T cell platforms to enhance the activation and direction of T cells in vivo. Tmunity's proprietary methodologies allow for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The founding team comprises experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, boasting a strong track record in conducting safe and effective cell and gene therapy trials. Additionally, Tmunity's manufacturing capabilities support multi-center clinical studies across various therapeutic areas, positioning the company to deliver next-generation personalized immunotherapies.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral, small-molecule drugs for the treatment of cancer and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company leverages its expertise in disease biology and medicinal chemistry to advance a pipeline of innovative therapeutic candidates. Key products include TERN-101, a non-bile acid farnesoid X receptor agonist, and TERN-201, an inhibitor of semicarbazide-sensitive amine oxidase. Terns Pharmaceuticals aims to address significant unmet medical needs both in China and globally through its efficient drug discovery model and extensive clinical development capabilities.

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Singlera Genomics Inc. specializes in developing genetic testing and molecular diagnostic technologies, particularly focusing on non-invasive methods. The company has created a methylation detection platform that enhances cancer screening for early tumor diagnosis and prevention. Its offerings include tumor diagnosis, personalized treatment options, non-invasive prenatal diagnosis, and pre-implantation genetic screening, along with customized scientific research services. With a commitment to precision medicine, Singlera Genomics aims to provide patients with early, accurate, and informative diagnoses. Founded in 2014, the company is headquartered in La Jolla, California, and operates research and development centers in Shanghai, China.

Tmunity Therapeutics, based in Philadelphia and incorporated in 2015, is a bio-therapeutics company focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. The company specializes in engineering T cells, utilizing novel T Cell Receptor (TCR) technologies, regulatory T cells (Treg), and universal engineered T cell platforms to enhance the activation and direction of T cells in vivo. Tmunity's proprietary methodologies allow for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The founding team comprises experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, boasting a strong track record in conducting safe and effective cell and gene therapy trials. Additionally, Tmunity's manufacturing capabilities support multi-center clinical studies across various therapeutic areas, positioning the company to deliver next-generation personalized immunotherapies.

Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Elpiscience Biopharmaceuticals Co., Ltd. operates as an immunology company that develops immunotherapies to treat cancer. The company is based in Pudong, China with an additional office in Suzhou, China.

Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. Its lead drug development programs include two clinical-stage allosteric SHP2 inhibitors, including JAB-3068, a SHP2 inhibitor for the treatment of patients with solid tumor; and JAB-3312, an oral small molecule anti-tumor agent. The company was founded in 2015 and is based in Beijing, China. Jacobio Pharmaceuticals Co., Ltd. is a subsidiary of Jacobio (HK) Pharmaceuticals Co., Limited.

ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

Veritas Genetics International Ltd. offers genetic testing services aimed at empowering individuals to improve their health and longevity. Based in Danvers, Massachusetts, the company collaborates with scientists, physicians, and patient advocates to develop comprehensive genetic testing solutions. Its advanced genetic technology surpasses traditional next-generation sequencing by detecting a broader range of gene variations. Veritas Genetics also provides a screening test focused on hereditary breast and ovarian cancer risk, facilitating informed decision-making for clinical researchers and healthcare providers. The company operates across North America, Asia, and Europe, striving to enhance the understanding of genetic health.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, with a focus on developing innovative antibody-drug conjugate therapies for late-stage multiple myeloma and prostate cancer. The company was established based on technology exclusively licensed from the University of California, San Francisco, and developed in the laboratory of Dr. Bin Liu. Fortis Therapeutics aims to enhance treatment options for patients suffering from advanced adenocarcinoma and neuroendocrine cancer, leveraging its proprietary platform to create targeted therapies that improve clinical outcomes in late-stage cancer treatment.

Singlera Genomics Inc. specializes in developing genetic testing and molecular diagnostic technologies, particularly focusing on non-invasive methods. The company has created a methylation detection platform that enhances cancer screening for early tumor diagnosis and prevention. Its offerings include tumor diagnosis, personalized treatment options, non-invasive prenatal diagnosis, and pre-implantation genetic screening, along with customized scientific research services. With a commitment to precision medicine, Singlera Genomics aims to provide patients with early, accurate, and informative diagnoses. Founded in 2014, the company is headquartered in La Jolla, California, and operates research and development centers in Shanghai, China.

IMPACT Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other serious diseases. Founded in 2009 and headquartered in Shanghai, China, the company is engaged in several research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, novel DNA damage response agents, and Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights, emphasizing the discovery of targeted anti-cancer therapies based on the principle of synthetic lethality. The company’s management team possesses extensive experience in drug development and management, with a strong background in pharmacology and biology, which supports its mission to provide innovative treatments for patients with life-threatening conditions.

Tmunity Therapeutics, based in Philadelphia and incorporated in 2015, is a bio-therapeutics company focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. The company specializes in engineering T cells, utilizing novel T Cell Receptor (TCR) technologies, regulatory T cells (Treg), and universal engineered T cell platforms to enhance the activation and direction of T cells in vivo. Tmunity's proprietary methodologies allow for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The founding team comprises experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, boasting a strong track record in conducting safe and effective cell and gene therapy trials. Additionally, Tmunity's manufacturing capabilities support multi-center clinical studies across various therapeutic areas, positioning the company to deliver next-generation personalized immunotherapies.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, dedicated to discovering and developing innovative immunomedicines for cancer and other immune-related diseases. The company’s lead product candidate, NC318, is currently undergoing Phase 2 clinical trials aimed at treating advanced or metastatic solid tumors. Additionally, NextCure is advancing NC410, an immunomedicine designed to counteract immune suppression through targeting an immune modulator known as Leukocyte-Associated Immunoglobulin-like Receptor 1. The company is also engaged in research programs evaluating novel immunomodulatory molecules, including antibodies in preclinical development that target specific immune modulators in inflamed tissues and tumor microenvironments. NextCure has established a license agreement with Yale University and collaborates with Eli Lilly and Company for research and development efforts. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets and develop first-in-class immunotherapy products.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Veritas Genetics International Ltd. offers genetic testing services aimed at empowering individuals to improve their health and longevity. Based in Danvers, Massachusetts, the company collaborates with scientists, physicians, and patient advocates to develop comprehensive genetic testing solutions. Its advanced genetic technology surpasses traditional next-generation sequencing by detecting a broader range of gene variations. Veritas Genetics also provides a screening test focused on hereditary breast and ovarian cancer risk, facilitating informed decision-making for clinical researchers and healthcare providers. The company operates across North America, Asia, and Europe, striving to enhance the understanding of genetic health.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibody drug candidates. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in treating multiple cancers and is featured on the National Reimbursement Drug List. Innovent has developed several other promising candidates, including biosimilars and bispecific antibodies for conditions such as non-Hodgkin’s lymphoma, autoimmune diseases, and advanced solid tumors. The company has established strategic collaborations with major global pharmaceutical firms, enhancing its research and development capabilities. Founded in 2011, Innovent has a strong management team with extensive experience in biologics, and it continues to expand its portfolio of therapeutic options while maintaining a commitment to innovation in the biopharmaceutical industry.

Provider of a data management platform intended to be used for clinical research. The company's data management platform digitalizes, standardizes and helps in structuring medical records, clinical research data and patients' data, enabling healthcare practitioners to enhance the efficiency and ease their work.

IMPACT Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other serious diseases. Founded in 2009 and headquartered in Shanghai, China, the company is engaged in several research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, novel DNA damage response agents, and Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights, emphasizing the discovery of targeted anti-cancer therapies based on the principle of synthetic lethality. The company’s management team possesses extensive experience in drug development and management, with a strong background in pharmacology and biology, which supports its mission to provide innovative treatments for patients with life-threatening conditions.

CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. Their premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. They are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.